Loading…
Drug regimens for visceral leishmaniasis in Mediterranean countries
Until the early 1990s, pentavalent antimony was the only documented first-line drug employed for the treatment of zoonotic visceral leishmaniasis (VL) in the Mediterranean, with reported cure rates exceeding 95% in immunocompetent patients. The emergence of antimony resistance in other endemic setti...
Saved in:
| Published in: | Tropical medicine & international health 2008-10, Vol.13 (10), p.1272-1276 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43 |
| container_end_page | 1276 |
| container_issue | 10 |
| container_start_page | 1272 |
| container_title | Tropical medicine & international health |
| container_volume | 13 |
| creator | Gradoni, Luigi Soteriadou, Ketty Louzir, Hecmi Dakkak, Allal Toz, Seray Ozensoy Jaffe, Charles Dedet, Jean-Pierre Campino, Lenea Cañavate, Carmen Dujardin, Jean-Claude |
| description | Until the early 1990s, pentavalent antimony was the only documented first-line drug employed for the treatment of zoonotic visceral leishmaniasis (VL) in the Mediterranean, with reported cure rates exceeding 95% in immunocompetent patients. The emergence of antimony resistance in other endemic settings and the increase in drug options have stimulated re-evaluation of the current therapeutic approaches and outcomes in Mediterranean countries. A scientific consortium ('LeishMed' network) collected updated information from collaborating clinical health centres of 11 endemic countries of Southern Europe, Northern Africa and the Middle East. In contrast with the previous situation, VL is now treated differently in the region, basically through three approaches: (1) In Northern Africa and in part of the Middle East, pentavalent antimony is still the mainstay for therapy, with no alternative drug options for treating relapses; (2) In some European countries and Israel, both pentavalent antimony and lipid-associated amphotericin B (AmB) formulations are used as first-line drugs, although in different patients' categories; (3) In other countries of Europe, mainly liposomal AmB is employed. Importantly, cure rates exhibited by different drugs, including antimonials in areas where they are still in routine use, are similarly high (greater-than-or-equal95%) in immunocompetent patients. Our findings show that antimony resistance is not an emerging problem in the Mediterranean. A country's wealth affects the treatment choice, which represents a balance between drug efficacy, toxicity and cost, and costs associated with patient's care. |
| doi_str_mv | 10.1111/j.1365-3156.2008.02144.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_pasteur_01375214v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20181803</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEoqXwFyBCoreEGX_vgUO1FFppKw60Z2uSdbZe5WOxN6X99zjNapE44YtH8jPjd943y3KEEtP5vC2RK1lwlKpkAKYEhkKUjy-y0-PDy-caCsa0OsnexLgFACGkep2doNFKGNSn2fJrGDd5cBvfuT7mzRDyBx9rF6jNW-fjfUe9p-hj7vv8xq393oVAvaM-r4ex3wfv4tvsVUNtdO8O91l29-3ydnlVrH58v15erIpaohYFaamEXFS6Yo1RVcOZ1EkHkG6kAXC0gDXViFVFSjVoDAouqVk4pxH5WvCzrJjn3lNrd8F3FJ7sQN5eXazsjuLejcECci2TGw-Y-POZ34Xh1-ji3nbTam2b9A9jtAzQoAGewI__gNthDH3axTKUEiQzE2RmqA5DjME1RwkIdkrFbu1kvp3Mt1Mq9jkV-5ha3x_mj1Xn1n8bDzEk4NMBoFhT2ySHax-PHAMtuFIT92XmfvvWPf23AHt7cz1Vqf_D3N_QYGkT0h93P5MNHFAKpUDwP9Vrryw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>215505283</pqid></control><display><type>article</type><title>Drug regimens for visceral leishmaniasis in Mediterranean countries</title><source>Wiley Online Library</source><creator>Gradoni, Luigi ; Soteriadou, Ketty ; Louzir, Hecmi ; Dakkak, Allal ; Toz, Seray Ozensoy ; Jaffe, Charles ; Dedet, Jean-Pierre ; Campino, Lenea ; Cañavate, Carmen ; Dujardin, Jean-Claude</creator><creatorcontrib>Gradoni, Luigi ; Soteriadou, Ketty ; Louzir, Hecmi ; Dakkak, Allal ; Toz, Seray Ozensoy ; Jaffe, Charles ; Dedet, Jean-Pierre ; Campino, Lenea ; Cañavate, Carmen ; Dujardin, Jean-Claude</creatorcontrib><description>Until the early 1990s, pentavalent antimony was the only documented first-line drug employed for the treatment of zoonotic visceral leishmaniasis (VL) in the Mediterranean, with reported cure rates exceeding 95% in immunocompetent patients. The emergence of antimony resistance in other endemic settings and the increase in drug options have stimulated re-evaluation of the current therapeutic approaches and outcomes in Mediterranean countries. A scientific consortium ('LeishMed' network) collected updated information from collaborating clinical health centres of 11 endemic countries of Southern Europe, Northern Africa and the Middle East. In contrast with the previous situation, VL is now treated differently in the region, basically through three approaches: (1) In Northern Africa and in part of the Middle East, pentavalent antimony is still the mainstay for therapy, with no alternative drug options for treating relapses; (2) In some European countries and Israel, both pentavalent antimony and lipid-associated amphotericin B (AmB) formulations are used as first-line drugs, although in different patients' categories; (3) In other countries of Europe, mainly liposomal AmB is employed. Importantly, cure rates exhibited by different drugs, including antimonials in areas where they are still in routine use, are similarly high (greater-than-or-equal95%) in immunocompetent patients. Our findings show that antimony resistance is not an emerging problem in the Mediterranean. A country's wealth affects the treatment choice, which represents a balance between drug efficacy, toxicity and cost, and costs associated with patient's care.</description><identifier>ISSN: 1360-2276</identifier><identifier>ISSN: 0365-6527</identifier><identifier>EISSN: 1365-3156</identifier><identifier>DOI: 10.1111/j.1365-3156.2008.02144.x</identifier><identifier>PMID: 18764817</identifier><language>eng</language><publisher>Oxford, UK: Oxford, UK : Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Africa, Northern ; Aged ; Aged, 80 and over ; Amphotericin B ; Amphotericin B - economics ; Amphotericin B - therapeutic use ; amphotéricine B ; Anfotericina B ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal agents ; antimoine pentavalent ; antimonio pentavalente ; Antimony Sodium Gluconate ; Antimony Sodium Gluconate - economics ; Antimony Sodium Gluconate - therapeutic use ; Antiprotozoal Agents ; Antiprotozoal Agents - economics ; Antiprotozoal Agents - therapeutic use ; Biological and medical sciences ; Child ; Child, Preschool ; Clinical Protocols ; Drug therapy ; Europe ; Female ; General aspects ; Human protozoal diseases ; Humans ; Immunocompromised Host ; Immunocompromised Host - drug effects ; Infectious diseases ; Israel ; Leishmania infantum ; leishmaniasis visceral Mediterránea ; Leishmaniasis, Visceral ; Leishmaniasis, Visceral - drug therapy ; Leishmaniasis, Visceral - economics ; Leishmaniasis, Visceral - immunology ; leishmaniose viscérale méditerranéenne ; Leshmaniasis ; Life Sciences ; Male ; Medical sciences ; Medication ; Mediterranean visceral leishmaniasis ; Meglumine ; Meglumine - economics ; Meglumine - therapeutic use ; Microbiology and Parasitology ; Middle Aged ; Middle East ; miltefosine ; miltéfosine ; Parasitic diseases ; Parasitology ; pentavalent antimony ; Pharmaceutical sciences ; Pharmacology. Drug treatments ; Protozoal diseases ; terapia ; therapeutics ; therapy ; thérapie</subject><ispartof>Tropical medicine & international health, 2008-10, Vol.13 (10), p.1272-1276</ispartof><rights>2008 Blackwell Publishing Ltd</rights><rights>2008 INIST-CNRS</rights><rights>Journal compilation © 2008 Blackwell Publishing Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43</citedby><cites>FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20743667$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18764817$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://riip.hal.science/pasteur-01375214$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Gradoni, Luigi</creatorcontrib><creatorcontrib>Soteriadou, Ketty</creatorcontrib><creatorcontrib>Louzir, Hecmi</creatorcontrib><creatorcontrib>Dakkak, Allal</creatorcontrib><creatorcontrib>Toz, Seray Ozensoy</creatorcontrib><creatorcontrib>Jaffe, Charles</creatorcontrib><creatorcontrib>Dedet, Jean-Pierre</creatorcontrib><creatorcontrib>Campino, Lenea</creatorcontrib><creatorcontrib>Cañavate, Carmen</creatorcontrib><creatorcontrib>Dujardin, Jean-Claude</creatorcontrib><title>Drug regimens for visceral leishmaniasis in Mediterranean countries</title><title>Tropical medicine & international health</title><addtitle>Trop Med Int Health</addtitle><description>Until the early 1990s, pentavalent antimony was the only documented first-line drug employed for the treatment of zoonotic visceral leishmaniasis (VL) in the Mediterranean, with reported cure rates exceeding 95% in immunocompetent patients. The emergence of antimony resistance in other endemic settings and the increase in drug options have stimulated re-evaluation of the current therapeutic approaches and outcomes in Mediterranean countries. A scientific consortium ('LeishMed' network) collected updated information from collaborating clinical health centres of 11 endemic countries of Southern Europe, Northern Africa and the Middle East. In contrast with the previous situation, VL is now treated differently in the region, basically through three approaches: (1) In Northern Africa and in part of the Middle East, pentavalent antimony is still the mainstay for therapy, with no alternative drug options for treating relapses; (2) In some European countries and Israel, both pentavalent antimony and lipid-associated amphotericin B (AmB) formulations are used as first-line drugs, although in different patients' categories; (3) In other countries of Europe, mainly liposomal AmB is employed. Importantly, cure rates exhibited by different drugs, including antimonials in areas where they are still in routine use, are similarly high (greater-than-or-equal95%) in immunocompetent patients. Our findings show that antimony resistance is not an emerging problem in the Mediterranean. A country's wealth affects the treatment choice, which represents a balance between drug efficacy, toxicity and cost, and costs associated with patient's care.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Africa, Northern</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amphotericin B</subject><subject>Amphotericin B - economics</subject><subject>Amphotericin B - therapeutic use</subject><subject>amphotéricine B</subject><subject>Anfotericina B</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal agents</subject><subject>antimoine pentavalent</subject><subject>antimonio pentavalente</subject><subject>Antimony Sodium Gluconate</subject><subject>Antimony Sodium Gluconate - economics</subject><subject>Antimony Sodium Gluconate - therapeutic use</subject><subject>Antiprotozoal Agents</subject><subject>Antiprotozoal Agents - economics</subject><subject>Antiprotozoal Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical Protocols</subject><subject>Drug therapy</subject><subject>Europe</subject><subject>Female</subject><subject>General aspects</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised Host - drug effects</subject><subject>Infectious diseases</subject><subject>Israel</subject><subject>Leishmania infantum</subject><subject>leishmaniasis visceral Mediterránea</subject><subject>Leishmaniasis, Visceral</subject><subject>Leishmaniasis, Visceral - drug therapy</subject><subject>Leishmaniasis, Visceral - economics</subject><subject>Leishmaniasis, Visceral - immunology</subject><subject>leishmaniose viscérale méditerranéenne</subject><subject>Leshmaniasis</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medication</subject><subject>Mediterranean visceral leishmaniasis</subject><subject>Meglumine</subject><subject>Meglumine - economics</subject><subject>Meglumine - therapeutic use</subject><subject>Microbiology and Parasitology</subject><subject>Middle Aged</subject><subject>Middle East</subject><subject>miltefosine</subject><subject>miltéfosine</subject><subject>Parasitic diseases</subject><subject>Parasitology</subject><subject>pentavalent antimony</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Protozoal diseases</subject><subject>terapia</subject><subject>therapeutics</subject><subject>therapy</subject><subject>thérapie</subject><issn>1360-2276</issn><issn>0365-6527</issn><issn>1365-3156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhiMEoqXwFyBCoreEGX_vgUO1FFppKw60Z2uSdbZe5WOxN6X99zjNapE44YtH8jPjd943y3KEEtP5vC2RK1lwlKpkAKYEhkKUjy-y0-PDy-caCsa0OsnexLgFACGkep2doNFKGNSn2fJrGDd5cBvfuT7mzRDyBx9rF6jNW-fjfUe9p-hj7vv8xq393oVAvaM-r4ex3wfv4tvsVUNtdO8O91l29-3ydnlVrH58v15erIpaohYFaamEXFS6Yo1RVcOZ1EkHkG6kAXC0gDXViFVFSjVoDAouqVk4pxH5WvCzrJjn3lNrd8F3FJ7sQN5eXazsjuLejcECci2TGw-Y-POZ34Xh1-ji3nbTam2b9A9jtAzQoAGewI__gNthDH3axTKUEiQzE2RmqA5DjME1RwkIdkrFbu1kvp3Mt1Mq9jkV-5ha3x_mj1Xn1n8bDzEk4NMBoFhT2ySHax-PHAMtuFIT92XmfvvWPf23AHt7cz1Vqf_D3N_QYGkT0h93P5MNHFAKpUDwP9Vrryw</recordid><startdate>200810</startdate><enddate>200810</enddate><creator>Gradoni, Luigi</creator><creator>Soteriadou, Ketty</creator><creator>Louzir, Hecmi</creator><creator>Dakkak, Allal</creator><creator>Toz, Seray Ozensoy</creator><creator>Jaffe, Charles</creator><creator>Dedet, Jean-Pierre</creator><creator>Campino, Lenea</creator><creator>Cañavate, Carmen</creator><creator>Dujardin, Jean-Claude</creator><general>Oxford, UK : Blackwell Publishing Ltd</general><general>Blackwell Publishing Ltd</general><general>Blackwell Science</general><general>Wiley-Blackwell</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>1XC</scope></search><sort><creationdate>200810</creationdate><title>Drug regimens for visceral leishmaniasis in Mediterranean countries</title><author>Gradoni, Luigi ; Soteriadou, Ketty ; Louzir, Hecmi ; Dakkak, Allal ; Toz, Seray Ozensoy ; Jaffe, Charles ; Dedet, Jean-Pierre ; Campino, Lenea ; Cañavate, Carmen ; Dujardin, Jean-Claude</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Africa, Northern</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amphotericin B</topic><topic>Amphotericin B - economics</topic><topic>Amphotericin B - therapeutic use</topic><topic>amphotéricine B</topic><topic>Anfotericina B</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal agents</topic><topic>antimoine pentavalent</topic><topic>antimonio pentavalente</topic><topic>Antimony Sodium Gluconate</topic><topic>Antimony Sodium Gluconate - economics</topic><topic>Antimony Sodium Gluconate - therapeutic use</topic><topic>Antiprotozoal Agents</topic><topic>Antiprotozoal Agents - economics</topic><topic>Antiprotozoal Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical Protocols</topic><topic>Drug therapy</topic><topic>Europe</topic><topic>Female</topic><topic>General aspects</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised Host - drug effects</topic><topic>Infectious diseases</topic><topic>Israel</topic><topic>Leishmania infantum</topic><topic>leishmaniasis visceral Mediterránea</topic><topic>Leishmaniasis, Visceral</topic><topic>Leishmaniasis, Visceral - drug therapy</topic><topic>Leishmaniasis, Visceral - economics</topic><topic>Leishmaniasis, Visceral - immunology</topic><topic>leishmaniose viscérale méditerranéenne</topic><topic>Leshmaniasis</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medication</topic><topic>Mediterranean visceral leishmaniasis</topic><topic>Meglumine</topic><topic>Meglumine - economics</topic><topic>Meglumine - therapeutic use</topic><topic>Microbiology and Parasitology</topic><topic>Middle Aged</topic><topic>Middle East</topic><topic>miltefosine</topic><topic>miltéfosine</topic><topic>Parasitic diseases</topic><topic>Parasitology</topic><topic>pentavalent antimony</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Protozoal diseases</topic><topic>terapia</topic><topic>therapeutics</topic><topic>therapy</topic><topic>thérapie</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gradoni, Luigi</creatorcontrib><creatorcontrib>Soteriadou, Ketty</creatorcontrib><creatorcontrib>Louzir, Hecmi</creatorcontrib><creatorcontrib>Dakkak, Allal</creatorcontrib><creatorcontrib>Toz, Seray Ozensoy</creatorcontrib><creatorcontrib>Jaffe, Charles</creatorcontrib><creatorcontrib>Dedet, Jean-Pierre</creatorcontrib><creatorcontrib>Campino, Lenea</creatorcontrib><creatorcontrib>Cañavate, Carmen</creatorcontrib><creatorcontrib>Dujardin, Jean-Claude</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Tropical medicine & international health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gradoni, Luigi</au><au>Soteriadou, Ketty</au><au>Louzir, Hecmi</au><au>Dakkak, Allal</au><au>Toz, Seray Ozensoy</au><au>Jaffe, Charles</au><au>Dedet, Jean-Pierre</au><au>Campino, Lenea</au><au>Cañavate, Carmen</au><au>Dujardin, Jean-Claude</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug regimens for visceral leishmaniasis in Mediterranean countries</atitle><jtitle>Tropical medicine & international health</jtitle><addtitle>Trop Med Int Health</addtitle><date>2008-10</date><risdate>2008</risdate><volume>13</volume><issue>10</issue><spage>1272</spage><epage>1276</epage><pages>1272-1276</pages><issn>1360-2276</issn><issn>0365-6527</issn><eissn>1365-3156</eissn><notes>http://dx.doi.org/10.1111/j.1365-3156.2008.02144.x</notes><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Until the early 1990s, pentavalent antimony was the only documented first-line drug employed for the treatment of zoonotic visceral leishmaniasis (VL) in the Mediterranean, with reported cure rates exceeding 95% in immunocompetent patients. The emergence of antimony resistance in other endemic settings and the increase in drug options have stimulated re-evaluation of the current therapeutic approaches and outcomes in Mediterranean countries. A scientific consortium ('LeishMed' network) collected updated information from collaborating clinical health centres of 11 endemic countries of Southern Europe, Northern Africa and the Middle East. In contrast with the previous situation, VL is now treated differently in the region, basically through three approaches: (1) In Northern Africa and in part of the Middle East, pentavalent antimony is still the mainstay for therapy, with no alternative drug options for treating relapses; (2) In some European countries and Israel, both pentavalent antimony and lipid-associated amphotericin B (AmB) formulations are used as first-line drugs, although in different patients' categories; (3) In other countries of Europe, mainly liposomal AmB is employed. Importantly, cure rates exhibited by different drugs, including antimonials in areas where they are still in routine use, are similarly high (greater-than-or-equal95%) in immunocompetent patients. Our findings show that antimony resistance is not an emerging problem in the Mediterranean. A country's wealth affects the treatment choice, which represents a balance between drug efficacy, toxicity and cost, and costs associated with patient's care.</abstract><cop>Oxford, UK</cop><pub>Oxford, UK : Blackwell Publishing Ltd</pub><pmid>18764817</pmid><doi>10.1111/j.1365-3156.2008.02144.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1360-2276 |
| ispartof | Tropical medicine & international health, 2008-10, Vol.13 (10), p.1272-1276 |
| issn | 1360-2276 0365-6527 1365-3156 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_pasteur_01375214v1 |
| source | Wiley Online Library |
| subjects | Adolescent Adult Africa, Northern Aged Aged, 80 and over Amphotericin B Amphotericin B - economics Amphotericin B - therapeutic use amphotéricine B Anfotericina B Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal agents antimoine pentavalent antimonio pentavalente Antimony Sodium Gluconate Antimony Sodium Gluconate - economics Antimony Sodium Gluconate - therapeutic use Antiprotozoal Agents Antiprotozoal Agents - economics Antiprotozoal Agents - therapeutic use Biological and medical sciences Child Child, Preschool Clinical Protocols Drug therapy Europe Female General aspects Human protozoal diseases Humans Immunocompromised Host Immunocompromised Host - drug effects Infectious diseases Israel Leishmania infantum leishmaniasis visceral Mediterránea Leishmaniasis, Visceral Leishmaniasis, Visceral - drug therapy Leishmaniasis, Visceral - economics Leishmaniasis, Visceral - immunology leishmaniose viscérale méditerranéenne Leshmaniasis Life Sciences Male Medical sciences Medication Mediterranean visceral leishmaniasis Meglumine Meglumine - economics Meglumine - therapeutic use Microbiology and Parasitology Middle Aged Middle East miltefosine miltéfosine Parasitic diseases Parasitology pentavalent antimony Pharmaceutical sciences Pharmacology. Drug treatments Protozoal diseases terapia therapeutics therapy thérapie |
| title | Drug regimens for visceral leishmaniasis in Mediterranean countries |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T04%3A46%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20regimens%20for%20visceral%20leishmaniasis%20in%20Mediterranean%20countries&rft.jtitle=Tropical%20medicine%20&%20international%20health&rft.au=Gradoni,%20Luigi&rft.date=2008-10&rft.volume=13&rft.issue=10&rft.spage=1272&rft.epage=1276&rft.pages=1272-1276&rft.issn=1360-2276&rft.eissn=1365-3156&rft_id=info:doi/10.1111/j.1365-3156.2008.02144.x&rft_dat=%3Cproquest_hal_p%3E20181803%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5174-a756459b7b2f86bf32578760a7f5800ea90dac11bba66f1881435af9ee7113d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=215505283&rft_id=info:pmid/18764817&rfr_iscdi=true |